Trial · NCT07908810
Threshold-Based Versus Range-Based Exercise Intensity Prescription in Cardiac Rehabilitation
NCT07908810, Not applicable, Not yet recruiting, Hasselt University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Threshold-Based Versus Range-Based Exercise Intensity Prescription in Cardiac Rehabilitation. Trials, record NCT07908810. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07908810
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Threshold-Based Versus Range-Based Exercise Intensity Prescription in Cardiac Rehabilitation
- NCT number
- NCT07908810
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 230 participants, estimated
- Lead sponsor
- Hasselt University
- Conditions
- Cardiovascular Diseases, Cardiac Rehabilitation
- Interventions
- Threshold-Based Aerobic Exercise Intensity Prescription, Range-Based Aerobic Exercise Intensity Prescription
- First posted
- 2026-11-02
- Last updated
- 2026-11-02
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Peak Oxygen Uptake (VO2peak) From Baseline to 4 Months | Baseline and 4 months (±1 week) | The primary outcome is the change in peak oxygen uptake (VO2peak), expressed in mL/kg/min, from baseline to 4 months. VO2peak will be measured using symptom-limited cardiopulmonary exercise testing (CPET) according to standardised procedures. Change will be calculated as the 4-month value minus the baseline value. The primary comparison will assess the between-group difference in mean change in VO2peak. |
| Secondary | Change in Peak Oxygen Uptake (VO2peak) From Baseline to 8 Months | Baseline and 8 months (±1 week) | Change in peak oxygen uptake (VO2peak), expressed in mL/kg/min, measured by cardiopulmonary exercise testing (CPET). Change will be calculated as the 8-month value minus the baseline value. The between-group difference in mean change will be evaluated to assess the sustainability of the intervention effect. |
| Secondary | Proportion of Participants Achieving a Clinically Meaningful Improvement in VO2peak | Baseline, 4 months (±1 week), and 8 months (±1 week) | Proportion of participants achieving an increase in VO2peak of at least 1 mL/kg/min compared with baseline, as measured by CPET. Participants will be classified as responders or non-responders at each follow-up assessment. The proportion of responders will be compared between treatment groups. |
| Secondary | Change in Disease-Specific Quality of Life Assessed by HeartQoL | Baseline, 4 months (±1 week), and 8 months (±1 week) | Change in disease-specific health-related quality of life measured using the HeartQoL questionnaire. HeartQoL is a validated patient-reported outcome instrument for patients with cardiovascular disease. Scores range from 0 to 3, with higher scores indicating better quality of life. Changes from baseline will be compared between treatment groups at 4 and 8 months. |
| Secondary | Change in Health-Related Quality of Life Assessed by EQ-5D-5L | Baseline, 4 months (±1 week), and 8 months (±1 week) | Change in health-related quality of life measured using the EQ-5D-5L questionnaire. The instrument assesses five dimensions of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Responses will be used to derive an EQ-5D-5L health utility index score using the applicable value set. Changes from baseline will be compared between treatment groups at 4 and 8 months. |
| Secondary | Adherence to Supervised Exercise Training (key secondary outcome) | Throughout the 15-week supervised intervention period (assessed at 4 months) | Adherence to supervised exercise training will be calculated as the percentage of supervised exercise sessions attended relative to the total number of sessions individually prescribed or scheduled during the 15-week intervention period. Data will be obtained from routine cardiac rehabilitation attendance records and the electronic case report form (eCRF). The target of 40 sessions will not be used as a fixed denominator, as the number of prescribed or scheduled sessions may vary between participants. |
| Secondary | Number of Supervised Exercise Sessions Attended | Throughout the 15-week supervised intervention period (assessed at 4 months) | Total number of supervised aerobic exercise training sessions attended during the 15-week cardiac rehabilitation programme, obtained from routine attendance records and the electronic case report form (eCRF). This measure represents treatment exposure and will be summarised and compared between treatment groups. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers6
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07908810
GET https://conductscience.org/api/trials/v1/NCT07908810/registered